124 related articles for article (PubMed ID: 22772894)
1. Elinogrel, an orally and intravenously available ADP-receptor antagonist. How does elinogrel affect a personalized antiplatelet therapy?
Müller KA; Geisler T; Gawaz M
Hamostaseologie; 2012; 32(3):191-4. PubMed ID: 22772894
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV
Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA;
Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518
[TBL] [Abstract][Full Text] [Related]
4. Elinogrel, an orally and intravenously available ADP-receptor antagonist.
Müller KAL; Geisler T; Gawaz M
Hamostaseologie; 2012; 32(3):191-194. PubMed ID: 29589361
[TBL] [Abstract][Full Text] [Related]
5. Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
Serebruany VL; Sibbing D; DiNicolantonio JJ
Cardiology; 2014; 127(1):20-4. PubMed ID: 24192670
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
Leonardi S; Rao SV; Harrington RA; Bhatt DL; Gibson CM; Roe MT; Kochman J; Huber K; Zeymer U; Madan M; Gretler DD; McClure MW; Paynter GE; Thompson V; Welsh RC
Am Heart J; 2010 Jul; 160(1):65-72. PubMed ID: 20598974
[TBL] [Abstract][Full Text] [Related]
7. Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding.
André P; DeGuzman F; Haberstock-Debic H; Mills S; Pak Y; Inagaki M; Pandey A; Hollenbach S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Jul; 338(1):22-30. PubMed ID: 21447613
[TBL] [Abstract][Full Text] [Related]
8. Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events.
Oestreich JH
Curr Opin Investig Drugs; 2010 Mar; 11(3):340-8. PubMed ID: 20178048
[TBL] [Abstract][Full Text] [Related]
9. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
White HD
Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
[TBL] [Abstract][Full Text] [Related]
10. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
Bernlochner I; Byrne RA; Kastrati A; Sibbing D
Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
[TBL] [Abstract][Full Text] [Related]
11. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Packard KA; Campbell JA; Knezevich JT; Davis EM
Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
[TBL] [Abstract][Full Text] [Related]
12. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW
Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867
[TBL] [Abstract][Full Text] [Related]
13. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
14. Elinogrel: pharmacological principles, preclinical and early phase clinical testing.
Ueno M; Rao SV; Angiolillo DJ
Future Cardiol; 2010 Jul; 6(4):445-53. PubMed ID: 20608816
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa SA; Jeske WP; Fareed J
Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
[TBL] [Abstract][Full Text] [Related]
16. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.
Hu L; Fan Z; Du H; Ni R; Zhang S; Yin K; Ye J; Zhang Y; Wei X; Zhang X; Gross PL; Kunapuli SP; Ding Z
Thromb Haemost; 2011 Dec; 106(6):1203-14. PubMed ID: 21946947
[TBL] [Abstract][Full Text] [Related]
17. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
Tan GM; Lam YY; Yan BP
Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
[TBL] [Abstract][Full Text] [Related]
18. [Prasugrel].
Darius H
Hamostaseologie; 2012; 32(3):186-90. PubMed ID: 22796754
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel in acute coronary syndrome: implications of recent study findings.
Duerschmied D; Bode C; Moser M
Expert Rev Cardiovasc Ther; 2010 Sep; 8(9):1215-29. PubMed ID: 20828343
[TBL] [Abstract][Full Text] [Related]
20. Personalizing antiplatelet therapy with clopidogrel.
Trenk D; Zolk O; Fromm MF; Neumann FJ; Hochholzer W
Clin Pharmacol Ther; 2012 Oct; 92(4):476-85. PubMed ID: 22948893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
